Header Logo

Connection

Gesine Meyer-Rath to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Gesine Meyer-Rath has written about Cost-Benefit Analysis.
Gesine Meyer-Rath
Connection Strength
3,807
Cost-Benefit Analysis
  1. Optimal HIV testing strategies for South Africa: a model-based evaluation of population-level impact and cost-effectiveness. Sci Rep. 2019 09 02; 9(1):12621.
    View in: PubMed
    Score: 0,585
  2. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS One. 2017; 12(10):e0186496.
    View in: PubMed
    Score: 0,515
  3. Cost-effectiveness of early identification of HIV infection. Lancet HIV. 2017 10; 4(10):e431-e432.
    View in: PubMed
    Score: 0,506
  4. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022 12; 9(12):e857-e867.
    View in: PubMed
    Score: 0,182
  5. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182.
    View in: PubMed
    Score: 0,171
  6. Role of data from cost and other economic analyses in healthcare decision-making for HIV, TB and sexual/reproductive health programmes in South Africa. Health Policy Plan. 2021 Nov 11; 36(10):1545-1551.
    View in: PubMed
    Score: 0,170
  7. The cost and intermediary cost-effectiveness of oral HIV self-test kit distribution across 11 distribution models in South Africa. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,166
  8. The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis. BMJ Glob Health. 2021 07; 6(Suppl 4).
    View in: PubMed
    Score: 0,166
  9. The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa. AIDS. 2020 05 01; 34(6):883-891.
    View in: PubMed
    Score: 0,153
  10. Cost-per-diagnosis as a metric for monitoring cost-effectiveness of HIV testing programmes in low-income settings in southern Africa: health economic and modelling analysis. J Int AIDS Soc. 2019 07; 22(7):e25325.
    View in: PubMed
    Score: 0,145
  11. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. J Acquir Immune Defic Syndr. 2018 10 01; 79(2):195-205.
    View in: PubMed
    Score: 0,137
  12. Evidence for scaling up HIV treatment in sub-Saharan Africa: A call for incorporating health system constraints. PLoS Med. 2017 02; 14(2):e1002240.
    View in: PubMed
    Score: 0,123
  13. Designing an optimal HIV programme for South Africa: Does the optimal package change when diminishing returns are considered? BMC Public Health. 2017 01 31; 17(1):143.
    View in: PubMed
    Score: 0,122
  14. The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. PLoS Med. 2015 Sep; 12(9):e1001869.
    View in: PubMed
    Score: 0,111
  15. Cost and outcomes of paediatric antiretroviral treatment in South Africa. AIDS. 2013 Jan 14; 27(2):243-50.
    View in: PubMed
    Score: 0,092
  16. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa. Sex Transm Dis. 2011 May; 38(5):401-9.
    View in: PubMed
    Score: 0,082
  17. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi. AIDS Care. 2009 Nov; 21(11):1388-94.
    View in: PubMed
    Score: 0,074
  18. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV. 2023 04; 10(4):e254-e265.
    View in: PubMed
    Score: 0,046
  19. Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models. Lancet Glob Health. 2023 Feb; 11(2):e244-e255.
    View in: PubMed
    Score: 0,046
  20. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. Lancet Glob Health. 2022 09; 10(9):e1298-e1306.
    View in: PubMed
    Score: 0,045
  21. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV. 2022 05; 9(5):e353-e362.
    View in: PubMed
    Score: 0,044
  22. Potential Impact and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance. J Infect Dis. 2021 04 23; 223(8):1345-1355.
    View in: PubMed
    Score: 0,041
  23. The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa. J Int AIDS Soc. 2018 03; 21(3).
    View in: PubMed
    Score: 0,033
  24. Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices. BMC Infect Dis. 2014 Jan 09; 14:14.
    View in: PubMed
    Score: 0,025
  25. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health. 2014 Jan; 2(1):e23-34.
    View in: PubMed
    Score: 0,025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.